Literature DB >> 31981754

Finite element analysis of bone strength in osteogenesis imperfecta.

Peter Varga1, Bettina M Willie2, Chris Stephan3, Kenneth M Kozloff3, Philippe K Zysset4.   

Abstract

As a dedicated experimentalist, John Currey praised the high potential of finite element (FE) analysis but also recognized its critical limitations. The application of the FE methodology to bone tissue is reviewed in the light of his enthusiastic and colorful statements. In the past decades, FE analysis contributed substantially to the understanding of structure-function properties in the hierarchical organization of bone and to the simulation of bone adaptation. The systematic experimental validation of FE analysis of bone strength in anatomical locations at risk of fracture led to its application in clinical studies to evaluate efficacy of antiresorptive or anabolic treatment of bone fragility. Beyond the successful analyses of healthy or osteoporotic bone, FE analysis becomes increasingly involved in the investigation of other fragility-related bone diseases. The case of osteogenesis imperfecta (OI) is exposed, the multiscale alterations of the bone tissue and the effect of treatment summarized. A few FE analyses attempting to answer open questions in OI are then reported. An original study is finally presented that explored the structural properties of the Brtl/+ murine model of OI type IV subjected to sclerostin neutralizing antibody treatment using microFE analysis. The use of identical material properties in the four-point bending FE simulations of the femora reproduced not only the experimental values but also the statistical comparisons examining the effect of disease and treatment. Further efforts are needed to build upon the extraordinary legacy of John Currey and clarify the impact of different bone diseases on the hierarchical mechanical properties of bone.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone strength; Drug treatment; Finite element analysis; John Currey; Osteogenesis imperfecta; Sclerostin neutralizing antibody

Year:  2020        PMID: 31981754      PMCID: PMC7383936          DOI: 10.1016/j.bone.2020.115250

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  121 in total

Review 1.  How well are bones designed to resist fracture?

Authors:  John D Currey
Journal:  J Bone Miner Res       Date:  2003-04       Impact factor: 6.741

2.  Predicting mouse vertebra strength with micro-computed tomography-derived finite element analysis.

Authors:  Jeffry S Nyman; Sasidhar Uppuganti; Alexander J Makowski; Barbara J Rowland; Alyssa R Merkel; Julie A Sterling; Todd L Bredbenner; Daniel S Perrien
Journal:  Bonekey Rep       Date:  2015-04-22

3.  Biomechanics of femoral deformity in osteogenesis imperfecta (OI): a quantitative approach to rehabilitation.

Authors:  Z Fan; P Smith; K Reiners; S Hassani; G Harris
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2004

4.  Sclerostin deficiency is linked to altered bone composition.

Authors:  Norbert Hassler; Andreas Roschger; Sonja Gamsjaeger; Ina Kramer; Sonja Lueger; Antoon van Lierop; Paul Roschger; Klaus Klaushofer; Eleftherios P Paschalis; Michaela Kneissel; Socrates Papapoulos
Journal:  J Bone Miner Res       Date:  2014-10       Impact factor: 6.741

5.  Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone.

Authors:  Nadja Fratzl-Zelman; Ingo Schmidt; Paul Roschger; Andreas Roschger; Francis H Glorieux; Klaus Klaushofer; Wolfgang Wagermaier; Frank Rauch; Peter Fratzl
Journal:  Bone       Date:  2014-12-29       Impact factor: 4.398

6.  Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.

Authors:  R Bargman; R Posham; A L Boskey; E DiCarlo; C Raggio; N Pleshko
Journal:  Osteoporos Int       Date:  2011-09-08       Impact factor: 4.507

7.  On the pathogenesis of osteogenesis imperfecta: some insights of the Utah paradigm of skeletal physiology.

Authors:  H M Frost
Journal:  J Musculoskelet Neuronal Interact       Date:  2003-03       Impact factor: 2.041

8.  Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations.

Authors:  Nadja Fratzl-Zelman; Ingo Schmidt; Paul Roschger; Francis H Glorieux; Klaus Klaushofer; Peter Fratzl; Frank Rauch; Wolfgang Wagermaier
Journal:  Bone       Date:  2013-12-01       Impact factor: 4.398

9.  A fracture risk assessment model of the femur in children with osteogenesis imperfecta (OI) during gait.

Authors:  Jessica M Fritz; Yabo Guan; Mei Wang; Peter A Smith; Gerald F Harris
Journal:  Med Eng Phys       Date:  2009-08-15       Impact factor: 2.242

10.  Unremodeled endochondral bone is a major architectural component of the cortical bone of the rat (Rattus norvegicus).

Authors:  A Shipov; P Zaslansky; H Riesemeier; G Segev; A Atkins; R Shahar
Journal:  J Struct Biol       Date:  2013-04-30       Impact factor: 2.867

View more
  2 in total

1.  Non-invasive prediction of the mouse tibia mechanical properties from microCT images: comparison between different finite element models.

Authors:  S Oliviero; M Roberts; R Owen; G C Reilly; I Bellantuono; E Dall'Ara
Journal:  Biomech Model Mechanobiol       Date:  2021-02-01

2.  Bone Fractures Numerical Analysis in a Femur Affected by Osteogenesis Imperfecta.

Authors:  Viridiana Ramírez-Vela; Luis Antonio Aguilar-Pérez; Juan Carlos Paredes-Rojas; Juan Alejandro Flores-Campos; Fernando ELi Ortiz-Hernández; Christopher René Torres-SanMiguel
Journal:  Children (Basel)       Date:  2021-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.